A review focused on what patients experience
Sjögren’s disease is a chronic autoimmune inflammatory condition. This review addresses a question distinct from controlling disease activity: to what extent do treatments improve quality of life and patient-reported symptoms?
The authors searched for publications covering the period from January 1, 2014, to February 2, 2026, mainly in MEDLINE and Embase, with supplementary searches. They included 53 publications representing 44 distinct studies, including randomized controlled trials and large case series.
The treatments examined included hydroxychloroquine, corticosteroids, rituximab, abatacept and several newer biologic treatments. Outcomes included Sjögren’s-specific questionnaires, such as the ESSPRI, as well as tools assessing fatigue and dryness.
Limited benefits for fatigue and dryness
According to the abstract, most systemic treatments did not provide meaningful improvement in fatigue or dry eyes and mouth. However, effect sizes, comparators and follow-up durations are not detailed. These details alone are not enough to quantify the benefits or compare the drugs precisely.
A focus group involving four patients complemented the review. Participants described persistent, co-occurring symptoms, including fatigue and cognitive difficulties that limited their daily activities. These accounts shed light on the experience of living with the disease, but this very small group cannot establish how common these difficulties are.
A finding that does not rule out all treatments
The important distinction concerns the outcome measured: limited improvement in patient-reported symptoms does not demonstrate a lack of effect on all manifestations of Sjögren’s disease. This review alone therefore does not justify stopping a treatment.
Participants wanted more comprehensive care that could relieve symptoms and prevent progression. This desire does not constitute evidence that so-called holistic approaches are effective. The main finding remains an inadequately met need: making a tangible improvement to patients’ daily lives.
Limitations to keep in mind
Only the PubMed abstract was consulted. Total participant numbers, numerical effects, follow-up durations, risk-of-bias assessments and heterogeneity of results are not specified in this excerpt. Funding and conflicts of interest were not checked.
What we can take away
This review highlights a gap between disease control goals and the relief patients experience. It cannot rank treatments or support recommending an alternative approach.
Sources and provenance
- Humanistic Burden of Sjögren's Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality of Life.
Source date: 2026-11-12.
Journal Article, Systematic Review · Résumé PubMed uniquement, texte intégral non consulté


